XOMA eligible for $5M milestone from FDA acceptance of Day One's NDA for tovorafenib in pediatric glioma

XOMA Royalty Corp

FDA accepted Day One Biopharmaceuticals' NDA for tovorafenib as monotherapy for relapsed/progressive pediatric low-grade glioma.
XOMA now eligible for a $5 million milestone payment from Day One under the tovorafenib royalty purchase agreement.
XOMA originally acquired up to $54M in milestones and mid-single digit royalties on tovorafenib from Viracta in March 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.